By analysing data through a more granular lens, including disaggregation by gender, we can uncover meaningful insights, identify differential responses, and ultimately drive more equitable outcomes for all patient groups. Doing so also supports alignment with regulatory expectations around inclusive and evidence based post-market surveillance.

Sabera Hyderally, Purdie Pascoe’s Head of US MedTech, recently facilitated an engaging, honest, and thought-provoking conversation with experts from across the MedTech and Diagnostics industry. The discussion explored how MedTech differs from other sectors, particularly pharmaceuticals, and what these differences mean for how we approach market research, innovation, and patient engagement. 

Attending this year’s RAPS Congress we were reminded of why we do what we do; at the heart of every conversation from regulatory reform to AI innovation there was one shared purpose: improving patients’ lives.